Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF88434 PET Study in Healthy Men
NCT04538014Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lu AF88434 in schizophrenia, sponsored by Lundbeck. Primary endpoints: Total distribution volume of [11C]-Lu AF88434 at Day 1, Concentration of Lu AF88434 derived from PET at Day 1 and 2 more. Started Aug 2020; status: completed.
02
Drugs
Lu AF88434
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04538014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538014.